ResApp Health Limited (ASX:RAP) says it has delivered excellent results in its Australian pediatric SmartCough C study.
The study has enrolled more than 1,100 children, where their cough sounds were used to diagnose respiratory disease.
Analysis of the dataset confirmed a high level of agreement between ResAppDx and the clinical diagnosis of patients.
This is the first study where ResAppDx has been used to diagnose a full range of respiratory diseases.
Shares in ResApp are trading 1.54 per cent higher at $0.33.